Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Grace Therapeutics, Inc. - Common Stock (NQ:GRCE)

2.755 +0.035 (+1.29%)
Streaming Delayed Price Updated: 3:51 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Grace Therapeutics, Inc. - Common Stock

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors
From Matinas BioPharma Holdings, Inc.
Via GlobeNewswire
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study
Grace Therapeutics' GTx-104 met its Phase 3 trial endpoint, showing clinical benefits over oral nimodipine. US NDA submission is expected in early 2025. 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.